Polyphosphate-Functionalized Nanoparticles for Rapid Hemostasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing hemostatic compositions struggle to rapidly initiate blood clotting and provide sufficient clot strength in severe bleeding situations, especially in remote or battlefield environments where immediate medical assistance is unavailable.
Innovation Solution
A hemostatic composition comprising nanoparticles functionalized with a polyphosphate polymer, which can be applied to wounds to promote rapid blood clotting and enhance clot strength, including medical devices like bandages and sponges, and methods for administering the composition to internal or external hemorrhages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If conventional hemostatic compositions are used, then blood clotting can be promoted, but the initiation of clotting is slow and clot strength is insufficient in severe bleeding situations
Solution Approach 1:
The invention uses a composite material consisting of inorganic nanoparticles (such as silica, calcium carbonate, or calcium phosphate) combined with organic polyphosphate polymers. This composite structure leverages the high surface area and reactivity of nanoparticles to rapidly activate the contact pathway, while the polyphosphate polymer provides structural support and enhances clot strength through calcium ion chelation and fibrin network stabilization. The synergistic interaction between the inorganic and organic components enables both rapid clot initiation and strong clot formation, resolving the contradiction between speed and reliability.
2Reliability
If hemostatic compositions are applied in remote or battlefield environments, then bleeding control is critical, but immediate medical assistance is unavailable
Solution Approach 1:
The hemostatic composition is designed to be self-activating upon contact with blood, requiring no external activation steps or specialized equipment. The inorganic nanoparticles automatically initiate the contact pathway when exposed to blood, and the polyphosphate polymer autonomously enhances clot strength through its chemical interactions with calcium ions and fibrin. This self-service mechanism ensures reliable hemostatic performance in remote environments where medical personnel and complex equipment are unavailable, while maintaining ease of operation through simple application to the wound site.
3Productivity
If rapid blood clotting is achieved, then bleeding control is improved, but adverse side effects may increase
Solution Approach 1:
The invention carefully controls key parameters of the hemostatic composition to achieve rapid clotting while minimizing adverse effects. The nanoparticle size is optimized to provide high surface area for rapid activation without causing excessive inflammation or embolism risks. The polyphosphate polymer concentration and molecular weight are tuned to enhance clot strength while maintaining biocompatibility and preventing unwanted thrombosis in non-wound areas. These parameter optimizations enable high productivity in hemostasis without proportionally increasing harmful side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively initiates blood clotting and enhances clot strength, even under challenging conditions, facilitating safe and rapid wound closure in emergency situations.
Implementation Method 1
The hemostatic composition includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle... effectively initiates blood clotting
Implementation Method 2
a polyphosphate polymer attached to the nanoparticle
Data Source
AI summary
A hemostatic composition is provided. The hemostatic composition includes a hemostatically effective amount of a hemostatic agent that includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle. Also provided are medical devices and methods of use to promote blood clotting.